Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Friday, May 22, 2015

Rebif® (interferon beta-1a) Data at CMSC Annual Meeting Highlights Clinical and MRI Predictors for Long Term Outcomes

ROCKLAND, Mass., May 21, 2015 /PRNewswire/ -- EMD Serono, Inc., the U.S. biopharmaceuticals business of Merck KGaA, Darmstadt, Germany, announced today that data about Rebif® (interferon beta-1a), the company's high-dose, high-frequency interferon beta for relapsing forms of multiple sclerosis, will be presented at the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), taking place from May 27-30 in Indianapolis, Indiana.
View photo
EMD Serono.
Data from 11 abstracts to be presented assess the efficacy of Rebif (interferon beta-1a) on MRI and clinical outcomes, and evaluate early predictors of no evidence of disease activity (NEDA) response, among other measures. The data also explores real-world evidence in MS, with analysis of time to first treatment with disease modifying drug as well as trends in treatment adherence among patients treated with self-injectables versus oral therapies.
"EMD Serono continues to evaluate the patient outcomes of Rebif, more specifically the important role it plays in the lives of those living with MS," said Dr. Rick Munschauer, Vice President, Medical Affairs, Neurology and Immunology, EMD Serono. "Our scientific and medical presence at this year's CMSC Annual Meeting is aimed at enhancing the understanding of our product and its effect on key measures in MS to help optimize patient care."

 Keep CURRENT with MS Views and NewsOPT-IN here


No comments: